La vendita allo scoperto per Butterfly Network dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Butterfly Network. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Butterfly Network (NYSE:BFLY) Azioni, Report sulle vendite allo scoperto

Butterfly Network

Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly enables the practical application of ultrasound information in the clinical workflow. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. With its small, handheld size, low cost, and simple user interface.

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

BFLY

HYFM

STIM

Le recenti operazioni degli insider che puntano su queste quattro penny stock. Scopri quali azioni stanno attirando l&#39;attenzione e perché.

4 penny stock sotto la lente d&#39;ingrandimento degli insider

Butterfly Network, Inc. Class A Common Stock

Butterfly Network Inc

U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Monday.
Shares of Sapiens International Corporation N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/SPNS/earnings">third-quarter financial results</a>.
Sapiens Intl posted third-quarter adjusted earnings of 37 cents per share, missing market estimates of 38 cents per share. The company's quarterly sales came in at $137.03 million versus expectations of $140.07 million.
Sapiens International shares dipped 21.5% to $30.98 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Sky Harbour Group Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NASDAQ">SKYH</a>) shares fell 9% to $10.55 in pre-market trading. Sky Harbour will report its third-quarter financial results on Tuesday, Nov. 12.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) shares dipped 5.7% to $23.05 in pre-market trading after gaining 13% on Friday.</li>
<li>Tempus AI, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) fell 5.2% to $69.85 in pre-market trading after jumping 30% on Friday.</li>
<li>Xeris Biopharma Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) dipped 4.9% to $3.30 in pre-market trading. Xeris Biopharma Holdings posted upbeat quarterly results on Friday.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) declined 4.7% to $15.06 in pre-market trading.</li>
<li>Lifeway Foods, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) declined 4.2% to $22.10 in pre-market trading after falling 8% on Friday.</li>
<li>Butterfly Network, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) fell 3.4% to $2.53 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41871463/dow-sp-500-notch-best-week-of-year-as-tesla-surges-post-trump-win-investor-sentiment-improves-fear-greed-index-remains-in-neutral-zone">Dow, S&amp;P 500 Notch Best Week Of Year As Tesla Surges Post Trump Win: Investor Sentiment Improves, Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Movers

LWAY

SKYH

SPNS

XERS

Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session

WIIM

Butterfly Network shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.

Guidance
Increased Revenue Guidance and improved Adjusted EBITDA guidance for the Fiscal Year 2024 to:
<ul>
<li>Revenue guidance of $79 million to $81 million or over 20% growth</li>
<li>Improved adjusted EBITDA guidance by $5 million to a loss of $42 million - $40 million</li>
</ul>

Earnings

Guidance

Health Care

General

Butterfly Network Expects 2024 Revenue Of $79M-$81M Versus Consensus Of $75M-$80M Vs $78.557M Est.

Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. The company reported quarterly sales of $20.56 million which beat the analyst consensus estimate of $19.01 million by 8.18 percent. This is a 33.33 percent increase over sales of $15.42 million the same period last year.

Butterfly Network Q3 2024 GAAP EPS $(0.08) Beats $(0.09) Estimate, Sales $20.56M Beat $19.01M Estimate

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares rose 58.1% to $0.95 during Thursday's after-market session. The company's market cap stands at $9.6 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares increased by 17.13% to $0.95. The company's market cap stands at $6.6 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 5.55% to $1.14. The company's market cap stands at $3.2 million. </li>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) shares moved upwards by 5.17% to $1.83. The market value of their outstanding shares is at $389.0 million. </li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) shares moved upwards by 5.16% to $22.99. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares moved upwards by 5.07% to $1.34. The market value of their outstanding shares is at $7.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock fell 6.5% to $0.45 during Thursday's after-market session. The market value of their outstanding shares is at $9.5 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares declined by 5.1% to $2.42. The market value of their outstanding shares is at $2.0 million. </li>
<li>Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) stock declined by 4.76% to $239.49. The market value of their outstanding shares is at $28.8 billion. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock declined by 4.69% to $1.22. The market value of their outstanding shares is at $3.9 million. </li>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) shares fell 4.59% to $6.25. The market value of their outstanding shares is at $669.6 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock declined by 4.5% to $6.59. The company's market cap stands at $85.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

KDLY

KLTO

NIVF

NRIX

PCSA

PHIO

TNGX

12 Health Care Stocks Moving In Thursday's After-Market Session

<ul>
<li>URMC increased ultrasound charge capture by 116% following system-wide deployment of Butterfly Network devices and Compass&#x2122; workflow software.</li>
<li>URMC's implementation results <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicalimagingscience.org%2Froadmap-to-success-blueprint-for-enterprise-wide-deployment-of-a-point-of-care-ultrasound-platform-inclusive-of-governance-policy-education-credentialing-and-quality-assurance%2F&amp;esheet=54122956&amp;newsitemid=20240917669860&amp;lan=en-US&amp;anchor=published&amp;index=1&amp;md5=c524e8d8dd5268a5f512603c0986c7de">published</a> on September 16, 2024 in the Journal of Clinical Imaging Science.</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.butterflynetwork.com&amp;esheet=54122956&amp;newsitemid=20240917669860&amp;lan=en-US&amp;anchor=Butterfly+Network%2C+Inc.&amp;index=2&amp;md5=feb818b2cf773f1940ad96704c5916ac">Butterfly Network, Inc.</a> ("Butterfly", "the Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today published a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbutterflynetwork.com%2Fcase-studies-urmc&amp;esheet=54122956&amp;newsitemid=20240917669860&amp;lan=en-US&amp;anchor=case+study&amp;index=3&amp;md5=edcc066ce0d00e71b94c89e2a2016144">case study</a> highlighting the positive impact of University of Rochester Medical Center's (URMC) transformative, system-wide deployment of Butterfly's point-of-care ultrasound (POCUS) devices and enterprise ultrasound platform, Compass&#x2122;. The results are backed by an <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicalimagingscience.org%2Froadmap-to-success-blueprint-for-enterprise-wide-deployment-of-a-point-of-care-ultrasound-platform-inclusive-of-governance-policy-education-credentialing-and-quality-assurance%2F&amp;esheet=54122956&amp;newsitemid=20240917669860&amp;lan=en-US&amp;anchor=academic+paper&amp;index=4&amp;md5=6901dde3885271a01a52a19178f2c937">academic paper</a> published yesterday, September 16, 2024, in the Journal of Clinical Imaging Science.

Biotech

University Of Rochester Medical Center Boosts Diagnostic Accuracy And Workflow Efficiency With Butterfly Network's Enterprise Ultrasound Solution; URMC Increased Ultrasound Charge Capture By 116% Following System-Wide Deployment Of Butterfly Network Devices And Compass Workflow Software

Butterfly Network shares are trading higher after Lake Street initiated coverage on the stock with a Buy rating and announced $3 price target.

Lake Street initiates coverage on Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) with a Buy rating and announces Price Target of $3.

Price Target

Initiation

Analyst Ratings

Lake Street Initiates Coverage On Butterfly Network with Buy Rating, Announces Price Target of $3

Shares of Butterfly Network (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NYSE">BFLY</a>) closed 26.9% higher on Sept. 4 after the company announced the commercial launch of its third-generation handheld point-of-care ultrasound system, Butterfly iQ3, in Europe. Investors are likely upbeat about the news due to the strong uptake of Butterfly iQ3 in the U.S. market following its February launch.
Butterfly iQ3 received EU MDR certification in March and is fully compliant with the Restriction of Hazardous Substances Directive. The device will currently be available in all European countries and the United Kingdom. It was launched in Canada during the second quarter. The company is now applying for regulatory approval for iQ3 in additional regions.
The Butterfly iQ3 is the company&#39;s most advanced portable ultrasound device in its portfolio which includes the second-generation iQ+ device. The Butterfly iQ3 uses BFLY&#39;s most advanced P4.3 chip that has double the processing power compared to iQ+ for best-in-class image quality, new advanced 3D imaging tools for easier use and a smaller, more ergonomic design. Moreover, the higher selling price of the device compared to iQ+ should accelerate the revenue growth rate.
BFLY&#39;s shares have gained 39.9% so far this year, significantly outperforming the industry&#39;s decline of 13.5% on the back of the rising adoption of Butterfly iQ3 in the U.S. market. The S&amp;P 500 Index has gained 15.9% in the same period.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/d3/76630.jpg?v=1658840067" /> 
Image Source: Zacks Investment Research
<h2>US Performance of BFLY&#39;s iQ3</h2>
Butterfly Network&#39;s 16% top-line growth in the second quarter was primarily driven by robust uptake of Butterfly iQ3 in the United States and additional sales from launch in Canada.&nbsp;Of the company&#39;s total online orders, 74% were for iQ3 during the quarter. iQ3 represented 89% of sales across all channels in Canada. Moreover, the company initiated a competitive device upgrade in the second quarter, allowing customers to turn their old non-butterfly product into a new iQ3. This represents an additional growth opportunity for the company as it upgraded over a thousand probes in the second quarter.
During the second quarter, iQ3 sales represented 50% of total unit sales, with 75% of total units sold in the United States.
<h2>BFLY&#39;s iQ3 to Improve Patient Care</h2>
The company&#39;s new advanced 3D capabilities, iQ Slice and iQ Fan for Butterly iQ3 make image capturing easier. iQ Slice helps to capture up to 46 ultrasound slices at a time across a wide angle. The imaging mode is designed to make it easier and faster to acquire excellent images without skilled maneuvering. On the other hand, iQ Fan is a dedicated lung tool that reduces the movements necessary to capture information and make informed clinical decisions.
These two new features come with Butterfly&#39;s existing robust feature list of more than 20 anatomical presets, six imaging modes and a collection of artificial intelligence, advanced imaging tools and a rich set of Calculation tools.
Apart from its rich features, Butterfly iQ3&#39;s smaller and ergonomic design is fueling its strong adoption in the United States and Canada, which is likely to continue to reflect in European markets as well. The device has a 17% smaller probe face and is 7% shorter in size than iQ+. The new device also comes with a stronger battery with up to 2 hours of thermal run time for outstanding continuous scanning and charges 2.5 times faster.
These features are helping the Butterfly iQ3 device to significantly enhance the echo image quality and the biplane mode for cannulation, which has already proven beneficial in managing patients with challenging IV access.
<div class="chart_embed">
<h3>Butterfly Network, Inc. Price</h3>
<img alt="Butterfly Network, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/75/1725523014.png" style="height:254px; width:572px" title="" />
Butterfly Network, Inc. price | Butterfly Network, Inc. Quote
</div>
<h2>BFLY&#39;s Zacks Rank &amp; Other Stocks to Consider</h2>
Butterfly Network currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are&nbsp;Boston Scientific&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>),&nbsp;Apyx Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apyx#NASDAQ">APYX</a>) and&nbsp;Universal Health Services (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>), each carrying a Zacks Rank #2 at present.
Boston Scientific has a long-term estimated growth rate of 12.6%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Boston Scientific&#39;s shares have risen 41.4% year to date compared with the&nbsp;industry&#39;s 12.3% growth.
Apyx Medicalhas an estimated growth rate of 20% for 2025. Its earnings missed estimates in each of the trailing four quarters, delivering a negative average surprise of 25.98%.
Apyx Medical&#39;s shares have lost 49.3% year to date against the&nbsp;industry&#39;s 12.3% growth.
Universal Health Services has a long-term estimated growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.58%.
Universal Health Services&#39; shares have risen 56.1% year to date compared with the&nbsp;industry&#39;s 48% growth.
<a href="https://www.zacks.com/stock/news/2331850/butterfly-network-s-stock-surges-on-iq3-device-launch-in-europe?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2331850">To read this article on Zacks.com click here.</a>

Earnings Beats

Large Cap

Penny Stocks

Small Cap

Tech

APYX

Butterfly Network's Stock Surges on iQ3 Device Launch in Europe

Butterfly Network shares are trading higher after the company launched its next-generation butterfly iQ3 in Europe, offering advanced 3d imaging and enhanced portability across 16 countries.

Butterfly Network Launches Next-Generation Butterfly iQ3 In Europe, Offering Advanced 3D Imaging And Enhanced Portability Across 16 Countries Including The UK, Germany, And France​

The Dow Jones index closed higher by more than 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Hydrofarm Holdings Group</h3>
<ul>
<li>The Trade: Hydrofarm Holdings Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYFM#NASDAQ">HYFM</a>) Director, CEO and Chairman of the Board William Douglas Toler <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 100,000 shares</a> at an average price of $0.50. To acquire these shares, it cost around $49,800.</li>
<li>What's Happening: On Aug. 8, Hydrofarm Holdings Group reported $54.8 million in net revenue for the second quarter representing a 13.1% year-over-year decrease from $63.1 million.</li>
<li>What Hydrofarm Holdings Group Does: Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies.</li>
</ul>
<h3 class="wp-block-heading">Neuronetics</h3>
<ul>
<li>The Trade: Neuronetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) Director Glenn P Muir acquired a total of 25,000 shares at an average price of $0.85. To acquire these shares, it cost around $21,250.</li>
<li>What's Happening: On Aug. 12, Neuronetics reported worse-than-expected second-quarter financial results and issued third-quarter revenue guidance below estimates.</li>
<li>What Neuronetics Does: Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.</li>
</ul>
<h3 class="wp-block-heading">Butterfly Network</h3>
<ul>
<li>The Trade: Butterfly Network, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) Director Larry Robbins <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 1,676,869 shares</a> at an average price of $1.00. The insider spent around $1.68 million to buy those shares.</li>
<li>What's Happening: On Aug. 28, ENDRA Life Sciences announced it was granted an extension to regain Nasdaq compliance status.</li>
<li>What Butterfly Network Does: Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound.</li>
</ul>
<h3 class="wp-block-heading">Castellum</h3>
<ul>
<li>The Trade: Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) General Counsel, Secretary Jay O Wright acquired a total of 61,597 shares at an average price of $0.16. The insider spent around $10,102 to buy those shares.</li>
<li>What's Happening: On Aug. 9, Castellum posted second-quarter revenue of $11.5 million.</li>
<li>What Castellum Does: Castellum Inc is engaged in providing information technology services.</li>
</ul>
Read More:<a href="https://www.benzinga.com/markets/24/08/40666406/top-2-real-estate-stocks-that-could-blast-off-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40666406/top-2-real-estate-stocks-that-could-blast-off-this-quarter">Top 2 Real Estate Stocks That Could Blast Off This Quarter</a></li>
</ul>

Butterfly Network And 3 Other Stocks Under $2 Executives Are Aggressively Buying

The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Nine Energy Service</h3>
<ul>
<li>The Trade: Nine Energy Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) 10% owner William Monroe <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 470,362 shares</a> at an average price of $1.58. To acquire these shares, it cost around $744,019.</li>
<li>What's Happening: On Aug. 5, Nine Energy Service posted downbeat quarterly results.</li>
<li>What Nine Energy Service Does: Nine Energy Service Inc is a North American onshore completion and production services provider</li>
</ul>
<h3 class="wp-block-heading">Custom Truck One Source</h3>
<ul>
<li>The Trade: Custom Truck One Source, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) President -Rentals Thomas R. Rich <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 26,200 shares </a>at an average price of $3.84. To acquire these shares, it cost around $100,653.</li>
<li>What's Happening: On Aug. 1, Custom Truck One Source reported worse-than-expected second-quarter financial results.</li>
<li>What Custom Truck One Source Does: Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America.</li>
</ul>
<h3 class="wp-block-heading">Butterfly Network</h3>
<ul>
<li>The Trade: Butterfly Network, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) President and CEO Joseph Devivo <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 104,000 shares</a> at an average price of $0.95. The insider spent around $98,519 to buy those shares.</li>
<li>What's Happening: On Aug. 1, Butterfly Network reported better-than-expected second-quarter financial results.</li>
<li>What Butterfly Network Does: Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40218858/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

CTOS

NINE

Butterfly Network And 2 Other Stocks Under $5 Insiders Are Buying

Butterfly Network shares are trading higher after the company reported better-than-expected Q2 financial results.

Guidance
Affirmed Revenue Guidance and improved Adjusted EBITDA guidance for the Fiscal Year 2024 to:
<ul>
<li>Affirm revenue guidance of $75 million to $80 million or approximately 15-20% growth</li>
<li>Improved adjusted EBITDA guidance by $5 million to a loss of $50 million - $45 million</li>
</ul>

Butterfly Network Affirms FY24 Revenue $75M-$80M Vs $76.33M Est.

Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50 percent. The company reported quarterly sales of $21.487 million which beat the analyst consensus estimate of $19.580 million by 9.74 percent. This is a 16.23 percent increase over sales of $18.487 million the same period last year.

Butterfly Network Q2 2024 Adj. EPS $(0.05) Beats $(0.10) Estimate, Sales $21.487M Beat $19.580M Estimate

<ul>
<li>With iQ+ Bladder, Butterfly expands outside its core point-of-care ultrasound market to better serve the bladder scanning market with its proprietary Ultrasound-on-Chip&#x2122; technology.</li>
<li>The bundled bladder solution includes an iQ+ Bladder probe, streamlined software, compact rolling cart, tablet and power splitter, paired with premium assembly.</li>
</ul>
Butterfly Network, Inc. ("Butterfly", "the Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today introduced its first specialty product, iQ+ Bladder&#x2122;, now available for purchase in the United States. The bundled solution includes an iQ+ Bladder probe, streamlined software, compact rolling cart, tablet and power splitter, paired with premium assembly. Combined, the solution offers a fit-for-purpose ultrasound-based bladder scanner that helps nurses get automated bladder volume calculations, with 3D visualizations, in seconds.

Butterfly Network Enters Bladder Scanning Market With iQ+ Bladder

<h3>Gainers</h3>
<ul>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares moved upwards by 52.84% to $2.95. The market value of their outstanding shares is at $154.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 35.41% to $1.3. The company's market cap stands at $4.6 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) stock rose 34.55% to $1.83. The company's market cap stands at $29.2 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock increased by 25.09% to $16.0. The company's market cap stands at $449.0 million. </li>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) stock increased by 24.52% to $0.98. The market value of their outstanding shares is at $203.9 million. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 12.5% to $0.1 during Thursday's pre-market session. The market value of their outstanding shares is at $1.2 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock fell 11.7% to $4.53. The company's market cap stands at $306.8 million. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) stock decreased by 11.06% to $1.93. The market value of their outstanding shares is at $191.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) shares decreased by 10.92% to $0.68. The market value of their outstanding shares is at $29.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock declined by 9.95% to $0.62. The company's market cap stands at $119.8 million. </li>
<li>Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) shares decreased by 9.86% to $9.42. The company's market cap stands at $634.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLR

APVO

ARAY

CNTX

CTMX

DBVT

PHAR

SKYE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Butterfly Network shares are trading higher after the company reported better-than-expected Q1 financial results.

Butterfly Network Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Butterfly Network GAAP EPS of -$0.08 beats by $0.01, revenue of $20.6M beats by $1.59M

Reports Q3 revenue $20.6M, consensus $19.01M. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, "The Butterfly ...

Butterfly Network reports Q3 adjusted EPS (5c), consensus (9c)

FY24 consensus $78.56M. Improved adjusted EBITDA guidance by $5M to a loss of ($42M)- ($40M). Published first on TheFly – the ultimate source for r...

Butterfly Network raises FY24 revenue view to $79M-$81 from $75M-$80M

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Butterfly Network (BFLY – Research Report) and Envoy...

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and Envoy Medical (COCH)

TD Cowen analyst Josh Jennings has maintained their bullish stance on BFLY stock, giving a Buy rating today. Josh Jennings has given his Buy rating...

Butterfly Network's Strong Financial Performance and Growth Drive Buy Rating

Butterfly Network, Inc. ( ($BFLY) ) has released its Q3 earnings. Here is a breakdown of the information Butterfly Network, Inc. presented to its i...

Butterfly Network Reports Strong Q3 Financial Performance

Butterfly Network ($BFLY), a developer of ultrasound imaging solutions, is revolutionizing medical imaging technology with products that offer whol...

Butterfly Network's (BFLY) Stock Surges 142% Year-To-Date on Ultrasound Technology

Meeting to be held on November 14 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...

Butterfly Network management to meet with Oppenheimer

ACDVF

ARCB

ARES

ASIX

CBOE

CHTR

CMLS

COCH

DBRG

ESNT

FUBO

GTLS

INTT

MSGS

OXLC

PRLB

TROW

Press Releases

Fierce Names Butterfly Network as a Fierce 50 Honoree of 2024

Small Cap Up Big Following Coverage Initiation And Buy Rating

University of Rochester Medical Center Boosts Diagnostic Accuracy and Workflow Efficiency with Butterfly Network's Enterprise Ultrasound Solution

Kansas City University Sets New Standard in Point-of-Care Ultrasound Education with AI-Guided Training Curriculum

Butterfly Network to Report Third Quarter 2024 Financial Results on November 1, 2024

HeartFocus Unveils AI-powered Education App for Conducting Clinical-Grade Heart Scans, Available on Butterfly Network's Handheld Ultrasound Devices

Butterfly Network Reports Third Quarter 2024 Financial Results

Butterfly Network to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024

Butterfly Network's iQ3™ Honored as the Best Medical Technology at 2024 Prix Galien USA Awards

Butterfly Network to Participate at the Virtual BTIG Digital Health Forum on November 25, 2024

Comments

Butterfly Network

Vendite allo scoperto

Butterfly Network (NYSE:BFLY) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO